54gene has created a trust to invest up to 5% of future proceeds from its commercial drug discovery programs to help establish a more sustainable and thriving cyclical ecosystem across Africa’s scientific development space and to ensure better quality healthcare delivery for the communities operated in, all in a move to promote its Commitment to Africa. The new trust is set to be managed by an advisory committee. With the growth in its commercial operations, 54gene’s commitment to Africa and the trust’s creation will ensure an African footprint and sustainable growth in global drug discovery across the continent.
Dr Abasi Ene-Obong, Founder & CEO said: “The initiative is designed to continue fostering partnerships within the African scientific body, to reflect the leadership of Africans in global drug discovery research, and to generate sustainable healthcare delivery systems that will ultimately benefit African communities participating in the scientific work that advances better outcomes for all.”
54gene is a health-tech startup founded by Dr Abasi Ene-Obong to address the significant gap in the global genomics market. The startup recently made an announcement on its move to give multiple scholarships to genomic scientists through its non-profit foundation, the African centre for Translational Genomics (ACTG). 54gene was also selected as a World Economic Forum Tech Pioneer 2021, in recognition of its work in healthcare technology advancements and innovations for social impact. The startup is focused on advancing African genomics and recognizes the importance of fostering knowledge transfer and community development.
